A7655

Atenolol

Name: Atenolol
Brand: SIGMA

≥98% (TLC), powder, β₁-adrenoceptor antagonist

Sinónimos:

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₁₄H₂₂N₂O₃

Número CAS:

29122-68-7

Peso molecular:

266.34

NACRES:

NA.77

PubChem Substance ID:

24277748

UNSPSC Code:

12352200

EC Number:

249-451-7

MDL number:

MFCD00057645

Nombre del producto

Atenolol, ≥98% (TLC), powder

InChI key

METKIMKYRPQLGS-UHFFFAOYSA-N

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

SMILES string

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H₂O: 0.3 mg/mL
DMSO: 18 mg/mL
ethanol: 3.4 mg/mL

originator

AstraZeneca

Quality Level

200

Gene Information

human ... ADRB1(153)
rat ... Adrb1(24925)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Bioactive Small Molecules

Application

Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.

Biochem/physiol Actions

Selective β₁-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Shelf-life of the solid is at least three years.

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.

Ganesha Rai et al.

Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)

Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we

Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.

Hsin-Hui Chiu et al.

Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)

To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31

Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.

Ronald V Lacro et al.

American heart journal, 165(5), 828-835 (2013-04-30)

The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened

Atenolol versus losartan in children and young adults with Marfan's syndrome.

Ronald V Lacro et al.

The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)

Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing

Vitamin B Mitigates Thoracic Aortic Dilation in Marfan Syndrome Mice by Restoring the Canonical TGF-β Pathway.

Tzu-Heng Huang et al.

International journal of molecular sciences, 22(21) (2021-11-14)

Thoracic aortic aneurysm (TAA) formation is a multifactorial process that results in diverse clinical manifestations and drug responses. Identifying the critical factors and their functions in Marfan syndrome (MFS) pathogenesis is important for exploring personalized medicine for MFS. Methylenetetrahydrofolate reductase

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico